CoChat
Sign Up
Cited by 72

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer

Sanoff, Hanna K., Moon, Dominic H., Moore, Dominic T., Boles, Jeremiah, Bui, Courtney, Blackstock, William, O'Neil, Bert H., Subramaniam, Somasundaram, McRee, Autumn J., Carlson, Cheryl, Lee, Michael S., Tepper, Joel E., Wang, Andrew Z.·2019·Nanomedicine: Nanotechnology, Biology and Medicine
DOI 10.1016/j.nano.2019.02.021PMC PMC7881832
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nano.2019.02.021

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 39

  1. Siegel, 2012, Cancer treatment and survivorship statistics, 2012, CA Cancer J Clin, 62, 220
  2. Bosset, 2006, EORTC Radiotherapy Group Trial 22921, Chemotherapy with preoperative radiotherapy in rectal cancer, N Engl J Med, 355, 1114, 10.1056/NEJMoa060829 · DOI · Paper page
  3. Roh, 2009, Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03, J Clin Oncol Off J Am Soc Clin Oncol, 27, 5124, 10.1200/JCO.2009.22.0467 · DOI
  4. Park, 2011, Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer, Cancer, 117, 3703, 10.1002/cncr.25943 · DOI
  5. O’Connell, 2014, Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04, J Clin Oncol Off J Am Soc Clin Oncol, 32, 1927, 10.1200/JCO.2013.53.7753 · DOI
  6. de Campos-Lobato, 2011, Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence, Ann Surg Oncol, 18, 1590, 10.1245/s10434-010-1506-1 · DOI
  7. Park, 2012, Neoadjuvant treatment response as an early response indicator for patients with rectal cancer, J Clin Oncol Off J Am Soc Clin Oncol, 30, 1770, 10.1200/JCO.2011.39.7901 · DOI
  8. Martin, 2012, Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer, Br J Surg, 99, 918, 10.1002/bjs.8702 · DOI
  9. Habr-Gama, 2004, Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results, Ann Surg, 240, 711, 10.1097/01.sla.0000141194.27992.32 · DOI
  10. Habr-Gama, 2011, Nonoperative approaches to rectal cancer: a critical evaluation, Semin Radiat Oncol, 21, 234, 10.1016/j.semradonc.2011.02.010 · DOI
  11. Maas, 2011, Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer, J Clin Oncol Off J Am Soc Clin Oncol, 29, 4633, 10.1200/JCO.2011.37.7176 · DOI
  12. Gérard, 2010, Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2, J Clin Oncol Off J Am Soc Clin Oncol, 28, 1638, 10.1200/JCO.2009.25.8376 · DOI · Paper page
  13. Allegra, 2015, Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial, J Natl Cancer Inst, 107, 10.1093/jnci/djv248 · DOI
  14. Willett, 2009, Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study, J Clin Oncol Off J Am Soc Clin Oncol, 27, 3020, 10.1200/JCO.2008.21.1771 · DOI
  15. Crane, 2010, Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer, Int J Radiat Oncol Biol Phys, 76, 824, 10.1016/j.ijrobp.2009.02.037 · DOI
  16. Landry, 2015, Oncologist, 20, 615, 10.1634/theoncologist.2015-0106 · DOI
  17. Horisberger, 2009, MARGIT (Mannheimer Arbeitsgruppe für Gastrointestinale Tumoren), Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial, Int J Radiat Oncol Biol Phys, 74, 1487, 10.1016/j.ijrobp.2008.10.014 · DOI
  18. Dewdney, 2012, Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C), J Clin Oncol Off J Am Soc Clin Oncol, 30, 1620, 10.1200/JCO.2011.39.6036 · DOI
  19. Kim, 2013, KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials, Int J Radiat Oncol Biol Phys, 85, 201, 10.1016/j.ijrobp.2012.03.048 · DOI
  20. Wang, 2014, Nanotechnology in radiation oncology, J Clin Oncol Off J Am Soc Clin Oncol, 32, 2879, 10.1200/JCO.2014.55.0699 · DOI
  21. Mi, 2016, Application of nanotechnology to cancer radiotherapy, Cancer Nanotechnol, 7, 10.1186/s12645-016-0024-7 · DOI
  22. Miller, 2013, Nanomedicine in chemoradiation, Ther Deliv, 4, 239, 10.4155/tde.12.147 · DOI
  23. Werner, 2012, Chemoradiotherapy of human tumors: novel approaches from nanomedicine, Curr Pharm Des, 18, 2830, 10.2174/138161212800626229 · DOI
  24. Tian, 2017, CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α, Cancer Res, 77, 112, 10.1158/0008-5472.CAN-15-2951 · DOI
  25. Clark, 2016, CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing, Proc Natl Acad Sci U S A, 113, 3850, 10.1073/pnas.1603018113 · DOI
  26. Eliasof, 2013, Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle, Proc Natl Acad Sci U S A, 110, 15127, 10.1073/pnas.1309566110 · DOI
  27. Mehta, 2003, Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer, Int J Radiat Oncol Biol Phys, 55, 132, 10.1016/S0360-3016(02)03863-4 · DOI
  28. Klautke, 2005, Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer, Br J Cancer, 92, 1215, 10.1038/sj.bjc.6602492 · DOI
  29. Glynne-Jones, 2007, A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study, Br J Cancer, 96, 551, 10.1038/sj.bjc.6603570 · DOI
  30. Weiss, 2013, First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies, Investig New Drugs, 31, 986, 10.1007/s10637-012-9921-8 · DOI
  31. Keefe, 2016, Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial, Ann Oncol Off J Eur Soc Med Oncol, 27, 1579, 10.1093/annonc/mdw188 · DOI
  32. Voss, 2017, A randomized phase 2 trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma, Ann Oncol Off J Eur Soc Med Oncol, 10.1093/annonc/mdx493 · DOI
  33. Lakhani, 2016, Evaluation of weekly dosing of CRLX101 alone and in combination with bevacizumab (bev) in patients (pts) with advanced solid tumors, Ann Oncol, 27, 393, 10.1093/annonc/mdw368.36 · DOI
  34. Simon, 1989, Optimal two-stage designs for phase II clinical trials, Control Clin Trials, 10, 1, 10.1016/0197-2456(89)90015-9 · DOI · Paper page
  35. Deng, 2016, Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial, J Clin Oncol Off J Am Soc Clin Oncol, 34, 3300, 10.1200/JCO.2016.66.6198 · DOI
  36. Rödel, 2015, Lancet Oncol, 16, 979, 10.1016/S1470-2045(15)00159-X · DOI
  37. Mohiuddin, 2013, Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer, Int J Radiat Oncol Biol Phys, 86, 523, 10.1016/j.ijrobp.2013.02.020 · DOI
  38. Velenik, 2010, A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer, Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol, 36, 244
  39. Uehara, 2013, Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial, Jpn J Clin Oncol, 43, 964, 10.1093/jjco/hyt115 · DOI

Cited by

Sorted by citations

Metadata

Authors
Sanoff, H. K., Moon, D. H., Moore, D. T., Boles, J., Bui, C., Blackstock, W., O'Neil, B. H., Subramaniam, S., McRee, A. J., Carlson, C., Lee, M. S., Tepper, J. E., & Wang, A. Z.
Venue
Nanomedicine: Nanotechnology, Biology and Medicine
Publisher
Elsevier BV
Published
2019-06
Volume
18
Pages
189-195
ISSN
1549-9634
DOI
10.1016/j.nano.2019.02.021
PMC
PMC7881832
Cited by
72
References
3
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review